link Origem:
date_range Inicia em 26 de abril de 2022
event_note Termina em 18 de junho de 2022
list 13 sequencias
assignment Nível: Intermediário
chat_bubble_outline Idioma : Inglês
language Subtítulos : Francês
card_giftcard 400 pontos
Ver avaliação

Informações principais

credit_card Free accesso
verified_user Certificado gratuito
timer 40 total de horas

Sobre o conteúdo

Vaccines are among the most effective public health interventions currently available. Smallpox has been eradicated and polio has almost disappeared worldwide through global vaccine campaigns. Most of the viral and bacterial infections that traditionally affected children have been drastically reduced thanks to national immunization programs in developed countries. Together with antibiotics and clean water, vaccines have increased life expectancy in both high- and low-income countries by eliminating many of the diseases that historically killed millions. It has been estimated that vaccines will have saved ~25 million deaths over 10 yr from 2010 to 2020, which is equivalent to five lives saved per minute. In terms of cost-effectiveness, it is estimated that $1 invested in vaccination results in a $10–44 healthcare saving.

In spite of the success of vaccination in preventing disease and its cost-effectiveness, several challenges remain such as increasing the diversity of the target populations by developing vaccines efficient in pregnant women who will protect their babies at early life, and in the elderly displaying a less efficient immune system to be primed. Besides preventing infectious diseases, a few examples of already available vaccines preventing virus-induced cancers, such as liver cancer due to the hepatitis B virus or cervical cancers due to papilloma viruses, pave the way for further development of anti-cancer vaccines. Recent advances in technology to identify the key antigens to induce efficient protective immunity and large-scale analysis of human immune responses offer to revisit the future of vaccine development in a more global health perspective, taking also into consideration the implementation of new sustainable models for the developing world. This course aims at covering all these aspects to give an overview of the discipline.

more_horiz Ler mais
more_horiz Ler menos


This MOOC is taught in english. Videos are subtitled in french and english

We recommend a good scientific background (such as a bachelor of science)

The estimated effort of work is 3h per week


Programa de estudos

Chapter 1 – Introduction to vaccinology, an integrative discipline- part 1/Introduction à la vaccinologie, une discipline intégrative-partie 1

  • W1-1: History of vaccines / Histoire des vaccins
  • W1-2: The legacy of smallpox eradication: Immunization, strategies to control, eliminate or eradicate vaccine-preventable diseases / Eradication de la variole: immunisation, stratégies de contrôle, d’élimination ou d’éradication des maladies infectieuses
  • W1-3 : Poliovirus : the next successful eradication story ? / Poliovirus: la prochaine éradication réussie ?
  • W1-4 : Epidemiology of infectious diseases: prerequisite for decision-making in vaccine development / Epidémiologie des maladies infectieuses: prérequis pour la prise de décision du développement d’un vaccin
  • W1-5 : Mathematical modeling of infectious diseases transmission / Modèles mathématiques de la transmission des maladies infectieuses
  • W1-6 : What a vaccinologist should know about the basic of immunology/ Les bases immunologiques indispensables à un vaccinologiste
  • W1-7 : Past, present and future of adjuvants in vaccination/ Passé, présent et future des adjuvants
  • W1-8 : Measurement of immune responses / Mesures des réponses immunes

Chapter 2 – Introduction to vaccinology, an integrative discipline- part 2/Introduction à la vaccinologie, une discipline intégrative-partie 2

  • W2-1 : Mémoire immunologique: le défi de conférer une immunité de longue Immunological memory: the challenge of conferring long-term protection /
  • W2-2 : Vaccinomics: the future of vaccinology? / Vaccinomics: the future de la vaccinologie ?
  • W2-3 : Maternal immunization/ Immunisation maternelle
  • W2-4 : Hurdles to vaccination in early life: revisiting immunological immaturity in human newborns / Difficultés à vacciner au début de la vie : mise à jour des données sur l’immaturité immunologique des nouveaux-nés.
  • W2-5 : Mucosal immunity: advantages and limitations in developing mucosal vaccines / Immunité muqueuse: avantages et limitations du développement des vaccins muqueux
  • W2-6 : Antigen discovery: from genomics to proteomics/ Découverte de nouveaux antigènes: de la génomique à la protéomique
  • W2-7 : Novel strategies for delivering vaccines/ Nouvelles stratégies pour délivrer les vaccins

Chapter 3 - Preclinical and clinical steps: Basic principles/Etapes précliniques et cliniques : principes de base>

  • W3-1 : Summary of clinical steps for vaccine development/ Résumé des étapes cliniques du développement d’un vaccin
  • W3-2 : Decision process in vaccine development / Processus de décision dans le développement vaccinal
  • W3-3 : GMP production: which prerequisites and how to proceed./ La production selon les bonnes pratiques : quels prérequis et comment procéder ?
  • W3-4 : Finding correlates of protection or the « Holy Grail » to avoiding large phase III clinical trials / Identifier les corrélats de protection ou la quête du Graal pour éviter de grands essais cliniques de phase III
  • W3-5 : Update on human challenge model for evaluation of vaccine efficacy/ Mise à jour des essais infectieux humains pour évaluer l’efficacité des vaccins

Chapter 4 - Update of vaccine development for the major infectious diseases/Mise à jour du développement de vaccins contre les principales maladies infectieuses

  • W4-1 : Success of glycoconjugate vaccines / Succès des vaccins glycoconjugués
  • W4-2 : Rotavirus vaccines: success and drawbacks./ Vaccins contre le rotavirus: succès et inconvénients
  • W4-3 : HPV: a vaccine against virus-induced cancer/ Le Vaccin HPV, un vaccin contre les cancers induits par les papilloma virus
  • W4-4 : Influenza vaccines : challenge of making a new vaccine each year/ Vaccins contre la grippe: le défi de faire un nouveau vaccin chaque année
  • W4-5 : Tuberculosis: BCG , new vaccines and biomarkers for vaccine trials / Tuberculose: BCG et nouveaux vaccins et biomarqueurs pour les essais cliniques

Chapter 5 - Vaccines remaining to be developed and implemented/Vaccins à développer et à mettre à disposition

  • W5-1 : Introduction and discussion on opportunities and challenges to control respiratory diseases / Introduction et discussion des opportunités et des défis pour le contrôle des maladies respiratoires
  • W5-2 : Towards the development of a respiratory syncytial virus (RSV) vaccine / Vers le développement d’un vaccin contre le virus respiratoire syncytial
  • W5-3 : Malaria epidemiology, pathophysiology, immune responses, and vaccine development./ Epidémiologie, physiopathologie, réponses immunes et développement de vaccins contre la malaria
  • W5-4 : Dengue epidemiology, pathophysiology, immune responses, and vaccine development / Epidémiologie, physiopathologie, réponses immunes et développement de vaccins contre la dengue
  • W5-5 : The burden of diarrheal diseases and prospects for vaccine impact/ Le fardeau des maladies diarrhéiques et l’impact de la vaccination
  • W5-6 : Challenges to HIV vaccines. / Défis dans le développement d’un vaccin HIV

Chapter 6 - Future challenges /Défis à venir

  • W6-1 : Innovation in future vaccines/ Innovation pour les vaccins de demain
  • W6-2 : Vaccines for the elderly / Vaccins pour les personnes âgées
  • W6-3 : Vaccines for public health emergencies? / Vaccins contre les maladies émergentes?
  • W6-4 : Globalization of vaccine production/ Globalisation de la production des vaccins
  • W6-5 : New public/philanthropic private partnerships for effective global health vaccines development: pandemic preparedness & response case study/ Nouveaux partenariats public/privés philantropiques pour le développement de vaccins dans une approche de santé globale : étude de cas pour être prêt en cas de pandémie
  • W6-6 : Vaccine hesitancy
  • W6-7 : Anti-cancer vaccines


This MOOC was created by the Education Department of the Institut Pasteur.

This MOOC was realized with the support of the Fondation IPSEN, under the eagis of Fondation de France.

This MOOC was realized with the support of the LaBex IBEID.

Social media / Réseaux sociaux

Conditions d'utilisation / Terms of use

Droits réservés / All rights reserved

Licence restrictive : la production relève de la propriété intellectuelle de son auteur et ne peut donc pas être réutilisée.

Restrictive License: your own production comes under intellectual property and thus can not be reused.

Frequently Asked Questions

What web browser should I use?

The Open edX platform works best with current versions of Chrome, Firefox or Safari, or with Internet Explorer version 9 and above.

See our list of supported browsers for the most up-to-date information.





Cécile Artaud, Richard Aspinall, Brigitte Autran, Michel Beurret, Stephen Brown, Joël Calmet, Helen Campbell, Chetan Chitnis, Behazine Combadière, Cecil Czerkinski, Francis Delpeyroux, Hazel Dockrell, Othmar Engelhardt, Mark Fletcher, Nathalie Garçon, Christiane Gerke, Marie-Lise Gougeon, Bruno Guy, Ruth Karron, Marie-Paule Kieny, Jean Lang, Odile Leroy, Arnaud Marchant,  Flor Munoz-Rivas,  Peter Openshaw, Maria Grazia Pizza, Stanley Plotkin  Rino Rappuoli, Rafick-Pierre Sekaly, Benoit Soubeyrand, Duncan Steele, Daniel Tarantola, Timo Vesikari, Peter White.


Criador do conteúdo

Institut Pasteur

O Institut Pasteur é uma fundação francesa privada, sem fins lucrativos, com sede em Paris, dedicada ao estudo da biologia, dos microrganismos, das doenças e das vacinas.

Criado em 1888 graças a uma subscrição pública internacional, tem o nome de Louis Pasteur1, o seu fundador e primeiro diretor, que em 1885 desenvolveu a primeira vacina contra a raiva.

Durante mais de um século, o Instituto Pasteur esteve na vanguarda da luta contra as doenças infecciosas. Em 1983, este organismo internacional de investigação foi o primeiro a isolar o vírus da imunodeficiência humana (VIH), o vírus que causa a síndrome da imunodeficiência adquirida (SIDA). Ao longo dos anos, foi responsável por descobertas revolucionárias que permitiram à medicina controlar doenças virulentas como a difteria, o tétano, a tuberculose, a poliomielite, a gripe, a febre amarela, a peste epidémica, a hepatite B e a SIDA.




France Université Numérique est le diffuseur des cours en ligne des établissements d’enseignement supérieur français et de leurs partenaires.

Il opère plusieurs plateformes de diffusion, dont la plus connue, FUN MOOC, est la première plateforme académique francophone mondiale. Grâce à de nombreux établissements partenaires, cette plateforme propose un vaste catalogue de cours s’enrichissant de jour en jour avec des thématiques variées et d’actualité.

Você é o criador deste MOOC?
Qual a sua apinião sobre esse recurso?